HIV And Cancer
Abstract
Malignancies in Human Immunodeficiency Virus (HIV) are divided into AIDsdefining and non AIDs-defining. In the Highly Active Antiretroviral Therapy
(HAART)-era the incidence of non AIDs-defining malignancies are increasing with better outcome as a result of improved CD4 counts and immune reconstitution,
still cancer remains an important cause of death in HIV patients.
References
1. Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults, MMWR. Atlanta, Centers for Disease Control, 1992.
2. Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008;197:1145.
3. Adolescents PoAGfAa: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents., in Services DoHaH (ed), 2009, pp 1–161.
4. Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis. 2009;48:633.
5. Dalgleish A, Beverley P, Clapham P et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984; 312: 20–4
6. Klatzmann D, Champagne E, Chamaret S et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 1984; 312: 24–7.
7. Yarchoan R, Uldrick TS, Little RF. AIDS-Related Malignancy. Principles & Practice of Oncology. 9th ed.Ch141.Lippincott;2011:2099-2111.
8. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J Clin Oncol. 2005;23:5224.
9. Uldrick TS, Polizzotto M, O’Mahony D, et al. Rituximab Combined with Liposomal Doxorubicin (R-Dox) in HIV-Infected Patients with Severe Kaposi Sarcoma-associated Herpes Virus (KSHV) – associated Multicentric Castleman Disease (MCD). Presented at: the 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies: Basic, Epidemiologic, and Clinical Research; April 26, 2010; Bethesda, MD.
10. Levine AM. Lymphoma complicating immunodeficiency disorders. Ann Oncol. 1994; 5(Suppl 2):29.
11. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006; 107:265.
12. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017.
13. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin’s disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol. 1995;13:1758.
14. Workowski RA, Benman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Morb Mortal Wkly Rep. 2006;55(RR11):1.
15. Goldie SJ, Freedberg KA, Weinstein MC, et al. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med. 2001;111:140.
16. Minkoff H, Zhong Y, Burk RD, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial
lesions in human immunodeficiency virus-positive women. J Infect Dis. 2010;201:681.
17. Frisch M, Biggar R J, Goedert J J. Human papillomavirus- associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500.
18. Silverberg MJ, Abrams DI. AIDS-defining and non- AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol. 2007;19:446.
19. Mosthaf FA, Hanhoff NJ, Goetzenich A, et al. High incidence of non-AIDS-defined cancers among HIVinfected patients in Germany: analysis of data collected
over a period of 3 years. Dtsch Med Wochenschr. 2006;131:1849.
20. Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis. 2009;48:633.
2. Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008;197:1145.
3. Adolescents PoAGfAa: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents., in Services DoHaH (ed), 2009, pp 1–161.
4. Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis. 2009;48:633.
5. Dalgleish A, Beverley P, Clapham P et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984; 312: 20–4
6. Klatzmann D, Champagne E, Chamaret S et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 1984; 312: 24–7.
7. Yarchoan R, Uldrick TS, Little RF. AIDS-Related Malignancy. Principles & Practice of Oncology. 9th ed.Ch141.Lippincott;2011:2099-2111.
8. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J Clin Oncol. 2005;23:5224.
9. Uldrick TS, Polizzotto M, O’Mahony D, et al. Rituximab Combined with Liposomal Doxorubicin (R-Dox) in HIV-Infected Patients with Severe Kaposi Sarcoma-associated Herpes Virus (KSHV) – associated Multicentric Castleman Disease (MCD). Presented at: the 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies: Basic, Epidemiologic, and Clinical Research; April 26, 2010; Bethesda, MD.
10. Levine AM. Lymphoma complicating immunodeficiency disorders. Ann Oncol. 1994; 5(Suppl 2):29.
11. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006; 107:265.
12. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017.
13. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin’s disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol. 1995;13:1758.
14. Workowski RA, Benman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Morb Mortal Wkly Rep. 2006;55(RR11):1.
15. Goldie SJ, Freedberg KA, Weinstein MC, et al. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med. 2001;111:140.
16. Minkoff H, Zhong Y, Burk RD, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial
lesions in human immunodeficiency virus-positive women. J Infect Dis. 2010;201:681.
17. Frisch M, Biggar R J, Goedert J J. Human papillomavirus- associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500.
18. Silverberg MJ, Abrams DI. AIDS-defining and non- AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol. 2007;19:446.
19. Mosthaf FA, Hanhoff NJ, Goetzenich A, et al. High incidence of non-AIDS-defined cancers among HIVinfected patients in Germany: analysis of data collected
over a period of 3 years. Dtsch Med Wochenschr. 2006;131:1849.
20. Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis. 2009;48:633.
Published
2019-09-13
How to Cite
Patel A A, Jain A P. (2019). HIV And Cancer. The Indian Practitioner, 67(6), 367-370. Retrieved from https://articles.theindianpractitioner.com/index.php/tip/article/view/798
Section
Original Article
